Can functional magnetic resonance imaging improve success rates in central nervous system drug discovery?

Expert Opinion on Drug Discovery

Volumn 6, Issue 6, 2011, Pages 597-617

  Borsook, David ^a   Hargreaves, Richard J ^b   Becerra, Lino ^a  

^a MCLEAN HOSPITAL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

animal models; brain; brain disease; drug development; drugs; functional imaging; translational; translational medicine

Indexed keywords

4 AMINOBUTYRIC ACID; BIOLOGICAL MARKER; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINE; DEOXYHEMOGLOBIN; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; GLUTAMIC ACID; GLYCINE; MORPHINE; N ACETYLASPARTIC ACID; NALOXONE; OXYHEMOGLOBIN; PITTSBURGH COMPOUND B;

ALZHEIMER DISEASE; BINDING SITE; BLOOD BRAIN BARRIER; BOLD SIGNAL; BRAIN ATROPHY; BRAIN REGION; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION TENSOR IMAGING; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; ELECTROPHYSIOLOGY; EVOKED RESPONSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENOTYPE; HUMAN; LIGAND BINDING; MEDICAL DECISION MAKING; MEDLINE; NERVE CELL NETWORK; NEUROANATOMY; NEUROIMAGING; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RESTING STATE NETWORK; REVIEW; RISK BENEFIT ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPIN LABELING; TREATMENT OUTCOME; TREATMENT RESPONSE; VOXEL BASED MORPHOMETRY;

EID: 79957568044     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2011.584529     Document Type: Review

References (161)

1. Kaitin KI, Dimasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin Pharmacol Ther 2011;6(2):183-8 Defines the problems related to the productivity of drug development.
2. Honig P, Lalonde R. The economics of drug development: a grim reality and a role for clinical pharmacology. Clin Pharmacol Ther 2010;87(3):247-51
3. Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9(7):560-74 A useful perspective on the benefits of biomarkers in CNS drug development.
4. Coghill RC. Individual differences in the subjective experience of pain: new insights into mechanisms and models. Headache 2010;50(9):1531-5 An important paper on individual differneces as they pertain to individual psychophysical and patterns of brain activations.
5. Vastag M, Keseru GM. Current in vitro and in silico models of blood-brain barrier penetration: a practical view. Curr Opin Drug Discov Devel 2009;12(1):115-24
6. Wong EH, Yocca F, Smith MA, Lee CM. Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective. Int J Neuropsychopharmacol 2010;13(9):1269-84
7. Gordian M, Singh N, Zemmel R, Elias T. Why products fail in phase III. In Vivo 2006;20:49-57
8. Matthews P. Preface, imaging in CNS drug discovery and development: implications for disease and therapy. Springer, New York; 2009
9. Borsook D, Becerra L, Hargreaves R. A role for fMRI in optimizing CNS drug development. Nat Rev Drug Discov 2006;5(5):411-24 A summary on the integration of imaging and drug development.
10. Borsook D, Becerra L. Using NMR approaches to drive the search for new CNS therapeutics. Curr Opin Investig Drugs 2010;11(7):771-8
11. Wise RG, Preston C. What is the value of human FMRI in CNS drug development? Drug Discov Today 2010;15(21-22):973-80 Evaluation of the costs of fMRI may demonstrate benefits beyond the science.
12. Das M. Central Nervous System (CNS) Biomarkers: Technologies and Global Markets. BBC Reports, 2010. Available from: http://www.bharatbook.com/detail. asp?id=158240&rt=Central-Nervous-System-CNSBiomarkers-Technologiesand- Global-Markets.html
13. Colburn WA. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development. J Clin Pharmacol 2000;40(12 Pt 2):1419-27
14. Carini C. Biomarkers: a valuable tool in clinical research and medical practice. IDrugs 2007;10(6):395-8 (Pubitemid 46944309)
15. Marrer E, Dieterle F. Promises of biomarkers in drug development-a reality check. Chem Biol Drug Des 2007;69(6):381-94 (Pubitemid 46955536)
16. Leiser SC, Dunlop J, Bowlby MR, Devilbiss DM. Aligning strategies for using EEG as a surrogate biomarker: a review of preclinical and clinical research. Biochem Pharmacol 2010. [Epub ahead of print]
17. Danhof M, Alvan G, Dahl SG, et al. Mechanism-based pharmacokineticpharmacodynamic modeling-a new classification of biomarkers. Pharm Res 2005;22(9):1432-7 (Pubitemid 41215882)
18. Polikar R, Tilley C, Hillis B, et al. MRI and PET data fusion for Alzheimer's disease diagnosis. Conf Proc IEEE Eng Med Biol Soc 2010;1:6058-61
19. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8(9):791-801
20. Schneider P, Hampel H, Buerger K. Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther 2009;15(4):358-74
21. Pritchard JF, Jurima-Romet M, Reimer ML, et al. Making better drugs: decision gates in non-clinical drug development. Nat Rev Drug Discov 2003;2(7):542-53 (Pubitemid 37361746)
22. Pritchard JF. Risk in CNS drug discovery: focus on treatment of Alzheimer's disease. BMC Neurosci 2008;9(Suppl 3):S1
23. Borsook D, Becerra L. CNS animal fMRI in pain and analgesia. Neurosci Biobehav Rev 2011;35(5):1125-43
24. Hargreaves RJ. The role of molecular imaging in drug discovery and development. Clin Pharmacol Ther 2008;83(2):349-53
25. Zilles K, Amunts K. Receptor mapping: architecture of the human cerebral cortex. Curr Opin Neurol 2009;22(4):331-9
26. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011;305(3):275-83 A pivotal study on a biomarker for Alzheimer's disease.
27. Bender A, Scheiber J, Glick M, et al. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2007;2(6):861-73
28. Geerts H. Mechanistic disease modeling as a useful tool for improving CNS drug research and development. Drug Dev Res 2011;In Press
29. Calabrese EJ. U-shaped dose response in behavioral pharmacology: historical foundations. Crit Rev Toxicol 2008;38(7):591-8
30. Logothetis NK. The neural basis of the blood-oxygen-level-dependent functional magnetic resonance imaging signal. Philos Trans R Soc Lond B Biol Sci 2002;357(1424):1003-37 (Pubitemid 34973714)
31. Viswanathan A, Freeman RD. Neurometabolic coupling in cerebral cortex reflects synaptic more than spiking activity. Nat Neurosci 2007;10(10):1308-12
32. Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci USA 1990;87(24):9868-72 (Pubitemid 120016545)
33. Belliveau JW, Kennedy DN Jr, McKinstry RC, et al. Functional mapping of the human visual cortex by magnetic resonance imaging. Science 1991;254(5032):716-19 (Pubitemid 21917395)
34. Logothetis NK. What we can do and what we cannot do with fMRI. Nature 2008;453(7197):869-78 A summary on the constraints of imaging.
35. Krekelberg B, Boynton GM, van Wezel RJ. Adaptation: from single cells to BOLD signals. Trends Neurosci 2006;29(5):250-6
36. Damoiseaux JS, Rombouts SA, Barkhof F, et al. Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci USA 2006;103(37):13848-53 The first studies to evaluate RSNs for robust stability over time in healthy subjects.
37. Barbalat G, Chambon V, Franck N, et al. Organization of cognitive control within the lateral prefrontal cortex in schizophrenia. Arch Gen Psychiatry 2009;66(4):377-86
38. Burstein R, Jakubowski M, Garcia-Nicas E, et al. Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol 2010;68(1):81-91 An example of translational utility of imaging and animal data.
39. Deco G, Jirsa VK, McIntosh AR. Emerging concepts for the dynamical organization of resting-state activity in the brain. Nat Rev Neurosci 2010;12(1):43-56
40. Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci USA 2003;100(1):253-8 A study that puts the value of RSN into the mainstream.
41. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA 2004;101(13):4637-42 One of the first studies to address the issue of the utility of RSNs to differentiate healty state from disease states.
42. Sorg C, Riedl V, Muhlau M, et al. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci USA 2007;104(47):18760-5 (Pubitemid 350210770)
43. Kelly C, de Zubicaray G, Di Martino A, et al. L-dopa modulates functional connectivity in striatal cognitive and motor networks: a double-blind placebo-controlled study. J Neurosci 2009;29(22):7364-78
44. Upadhyay J, Maleki N, Potter J, et al. Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. Brain 2010;133(Pt 7):2098-114 Drugs change the brain and imaging may be useful in defining long-term effects of drug action on neural circuits.
45. Guye M, Bartolomei F, Ranjeva JP. Imaging structural and functional connectivity: towards a unified definition of human brain organization? Curr Opin Neurol 2008;21(4):393-403
46. Reijneveld JC, Ponten SC, Berendse HW, Stam CJ. The application of graph theoretical analysis to complex networks in the brain. Clin Neurophysiol 2007;118(11):2317-31 (Pubitemid 47539271)
47. Bassett DS, Bullmore ET. Human brain networks in health and disease. Curr Opin Neurol 2009;22(4):340-7 A summary of imaging in evaluating and comparing whole human brain structural and functional networks.
48. Cauda F, Sacco K, D'Agata F, et al. Low-frequency BOLD fluctuations demonstrate altered thalamocortical connectivity in diabetic neuropathic pain. BMC Neurosci 2009;10:138
49. Golay X, Petersen ET. Arterial spin labeling: benefits and pitfalls of high magnetic field. Neuroimaging Clin N Am 2006;16(2):259-68, x
50. Detre JA, Wang J, Wang Z, Rao H. Arterial spin-labeled perfusion MRI in basic and clinical neuroscience. Curr Opin Neurol 2009;22(4):348-55 ASL has the potential of quantitiative measures of blood flow that correlate with neural activity.
51. Chen Y, Wan HI, O'Reardon JP, et al. Quantification of cerebral blood flow as biomarker of drug effect: arterial spin labeling phMRI after a single dose of oral citalopram. Clin Pharmacol Ther 2011;89(2):251-8
52. Becerra L, Harter K, Gonzalez RG, Borsook D. Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioid-naive healthy volunteers. Anesth Analg 2006;103(1):208-16, table of contents
53. Borras MC, Becerra L, Ploghaus A, et al. fMRI measurement of CNS responses to naloxone infusion and subsequent mild noxious thermal stimuli in healthy volunteers. J Neurophysiol 2004;91(6):2723-33 (Pubitemid 38649778)
54. Bifone A, Gozzi A. Functional and pharmacological MRI in understanding brain function at a systems level. Curr Top Behav Neurosci 2011;7:323-57
55. Vanderheyden JL. The use of imaging in preclinical drug development. Q J Nucl Med Mol Imaging 2009;53(4):374-81
56. Delatour B, Epelbaum S, Petiet A, Dhenain M. In vivo imaging biomarkers in mouse models of Alzheimer's disease: are we lost in translation or breaking through? Int J Alzheimers Dis 2010;2010. pii: 604853
57. Sakoglu U, Upadhyay J, Chin CL, et al. Paradigm shift in translational neuroimaging of CNS disorders. Biochem Pharmacol 2010
58. Becerra L, Chang PC, Bishop J, Borsook D. CNS activation maps in awake rats exposed to thermal stimuli to the dorsum of the hindpaw. Neuroimage 2011;54(2):1355-66
59. Huang W, Heffernan ME, Li Z, et al. Fear induced neuronal alterations in a genetic model of depression: An fMRI study on awake animals. Neurosci Lett 2010;489(2):74-8
60. Chin CL, Upadhyay J, Marek GJ, et al. Awake rat pharmacological MRI as a translational pharmacodynamic biomarker: mGluR2/3 agonist modulation of ketamine-induced bold Signals. J Pharmacol Exp Ther 2011;336(3):709-15
61. Borsook D, Pendse G, Aiello-Lammens M, et al. CNS response to a thermal stressor in human volunteers and awake rats may predict clinical utility of analgesics. Drug Dev Res 2007;68(1):23-41 (Pubitemid 46878003)
62. Littlewood CL, Cash D, Dixon AL, et al. Using the BOLD MR signal to differentiate the stereoisomers of ketamine in the rat. Neuroimage 2006;32(4):1733-46 (Pubitemid 44332281)
63. Borsook D, Burstein R, Becerra L. Functional imaging of the human trigeminal system: opportunities for new insights into pain processing in health and disease. J Neurobiol 2004;61(1):107-25 (Pubitemid 39287773)
64. Greenwald MK, Johanson CE, Moody DE, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003;28(11):2000-9 (Pubitemid 37412109)
65. Alzheimer's Disease Neuroimaging Initiative. 2009. Available from: http://www.adniinfo.org/
66. Serra L, Cercignani M, Lenzi D, et al. Grey and white matter changes at different stages of Alzheimer's disease. J Alzheimers Dis Sep 11 2009. [Epub ahead of print]
67. Mechelli A, Price C, Friston K, Ashburner J. Voxel-based morphometry of the human brain: methods and applications. Curr Med Imaging Rev 2005;1:1-9
68. Fjell AM, Westlye LT, Amlien I, et al. Minute effects of sex on the aging brain: a multisample magnetic resonance imaging study of healthy aging and Alzheimer's disease. J Neurosci 2009;29(27):8774-83
69. de Jong LW, van der Hiele K, Veer IM, et al. Strongly reduced volumes of putamen and thalamus in Alzheimer's disease: an MRI study. Brain 2008;131(Pt 12):3277-85 Specific regions that are realtively easily measured may confer useful markers of disease.
70. Hamilton JP, Siemer M, Gotlib IH. Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Mol Psychiatry 2008;13(11):993-1000
71. Jovicich J, Czanner S, Han X, et al. MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. Neuroimage 2009;46(1):177-92
72. Rosso IM, Cintron CM, Steingard RJ, et al. Amygdala and hippocampus volumes in pediatric major depression. Biol Psychiatry 2005;57(1):21-6 (Pubitemid 39647587)
73. Apkarian AV, Sosa Y, Sonty S, et al. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci 2004;24(46):10410-15 An important study implicating chronic pain on neural integrity as measured by gray matter volume. This approach has been used across a number of CNS disease states that are not classically neurodegenerative in nature.
74. Kuchinad A, Schweinhardt P, Seminowicz DA, et al. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain? J Neurosci 2007;27(15):4004-7 (Pubitemid 46597143)
75. May A. Chronic pain may change the structure of the brain. Pain 2008;137(1):7-15
76. Battaglini M, Giorgio A, Stromillo ML, et al. Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis. J Neurol Sci 2009;282(1-2):55-60
77. Kantarci K, Knopman DS, Dickson DW, et al. Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology 2008;248(1):210-20
78. Alexander AL, Lee JE, Lazar M, Field AS. Diffusion tensor imaging of the brain. Neurotherapeutics 2007;4(3):316-29 (Pubitemid 46962420)
79. Mukherjee P, Berman JI, Chung SW, et al. Diffusion tensor MR imaging and fiber tractography: theoretic underpinnings. AJNR Am J Neuroradiol 2008;29(4):632-41 (Pubitemid 351571538)
80. Hasan KM, Walimuni IS, Abid H, Hahn KR. A review of diffusion tensor magnetic resonance imaging computational methods and software tools. Comput Biol Med Nov 17 2010. [Epub ahead of print]
81. Roosendaal SD, Geurts JJ, Vrenken H, et al. Regional DTI differences in multiple sclerosis patients. Neuroimage 2009;44(4):1397-403
82. Shimony JS, Sheline YI, D'Angelo G, et al. Diffuse microstructural abnormalities of normal-appearing white matter in late life depression: a diffusion tensor imaging study. Biol Psychiatry 2009;66(3):245-52
83. Pfefferbaum A, Rosenbloom M, Rohlfing T, Sullivan EV. Degradation of association and projection white matter systems in alcoholism detected with quantitative fiber tracking. Biol Psychiatry 2009;65(8):680-90
84. Stricker NH, Schweinsburg BC, Delano-Wood L, et al. Decreased white matter integrity in late-myelinating fiber pathways in Alzheimer's disease supports retrogenesis. Neuroimage 2009;45(1):10-16
85. Assaf Y, Pasternak O. Diffusion tensor imaging (DTI)-based white matter mapping in brain research: a review. J Mol Neurosci 2008;34(1):51-61 (Pubitemid 351378086)
86. Upadhyay J, Knudsen J, Anderson J, et al. Noninvasive mapping of human trigeminal brainstem pathways. Magn Reson Med 2008;60(5):1037-46
87. Soares DP, Law M. Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol 2009;64(1):12-21 A useful review.
88. Ross B, Tran T, Bhattacharya P, et al. Application of NMR spectroscopy in medicinal chemistry and drug discovery. Curr Top Med Chem 2010;11(1):93-114
89. Rodriguez I, Perez-Rial S, Gonzalez-Jimenez J, et al. Magnetic resonance methods and applications in pharmaceutical research. J Pharm Sci 2008;97(9):3637-65
90. Gruetter R, Adriany G, Choi IY, et al. Localized in vivo 13C NMR spectroscopy of the brain. NMR Biomed 2003;16(6-7):313-38 (Pubitemid 38008361)
91. Henry PG, Tkac I, Gruetter R. 1H-localized broadband 13C NMR spectroscopy of the rat brain in vivo at 9.4 T. Magn Reson Med 2003;50(4):684-92 (Pubitemid 37187831)
92. de Graaf RA, Mason GF, Patel AB, et al. In vivo 1H-[13C]-NMR spectroscopy of cerebral metabolism. NMR Biomed 2003;16(6-7):339-57
93. Wijnen JP, Scheenen TW, Klomp DW, Heerschap A. 31P magnetic resonance spectroscopic imaging with polarisation transfer of phosphomono- and diesters at 3 T in the human brain: relation with age and spatial differences. NMR Biomed 2010;23(8):968-76
94. Mellon EA, Pilkinton DT, Clark CM, et al. Sodium MR imaging detection of mild Alzheimer disease: preliminary study. AJNR Am J Neuroradiol 2009;30(5):978-84
95. Friedman SD, Shaw DW, Ishak G, et al. The use of neuroimaging in the diagnosis of mitochondrial disease. Dev Disabil Res Rev 2010;16(2):129-35
96. Sturrock A, Laule C, Decolongon J, et al. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology 2010;75(19):1702-10
97. Landrieu I, Leroy A, Smet-Nocca C, et al. NMR spectroscopy of the neuronal tau protein: normal function and implication in Alzheimer's disease. Biochem Soc Trans 2010;38(4):1006-11
98. Metastasio A, Rinaldi P, Tarducci R, et al. Conversion of MCI to dementia: role of proton magnetic resonance spectroscopy. Neurobiol Aging 2006;27(7):926-32
99. de Visser SJ, van der Post J, Pieters MS, et al. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol 2001;51(2):119-32 An example of attempts to ustilize imaging to define the utility of pharmacological agents in healthy volunteers.
100. de Visser SJ, van der Post JP, de Waal PP, et al. Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol 2003;55(1):39-50
101. Wagner JA. Strategic approach to fit-for-purpose biomarkers in drug development. Annu Rev Pharmacol Toxicol 2008;48:631-51 A pivotal paper on the assesment of biomarker use in drgu development.
102. Rossini PM, Dal Forno G. Integrated technology for evaluation of brain function and neural plasticity. Phys Med Rehabil Clin N Am 2004;15(1):263-306 (Pubitemid 38210043)
103. Miller DH. Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx 2004;1(2):284-94 (Pubitemid 46591886)
104. Endo T, Spenger C, Westman E, et al. Reorganization of sensory processing below the level of spinal cord injury as revealed by fMRI. Exp Neurol 2008;209(1):155-60
105. Kaas JH, Qi HX, Burish MJ, et al. Cortical and subcortical plasticity in the brains of humans, primates, and rats after damage to sensory afferents in the dorsal columns of the spinal cord. Exp Neurol 2008;209(2):407-16 (Pubitemid 351174131)
106. Metz AE, Yau HJ, Centeno MV, et al. Morphological and functional reorganization of rat medial prefrontal cortex in neuropathic pain. Proc Natl Acad Sci USA 2009;106(7):2423-8
107. Grachev ID, Fredrickson BE, Apkarian AV. Abnormal brain chemistry in chronic back pain: an in vivo proton magnetic resonance spectroscopy study. Pain 2000;89(1):7-18
108. Prescot A, Becerra L, Pendse G, et al. Excitatory neurotransmitters in brain regions in interictal migraine patients. Mol Pain 2009;5:34
109. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007;6(4):287-93 (Pubitemid 46505879)
110. Borsook D, Bleakman D, Hargreaves R, et al. A 'BOLD' experiment in defining the utility of fMRI in drug development. Neuroimage 2008;42(2):461-6 A practical example of consortia appraoches to evaluating and implementing functional imaging in drug development.
111. Lu H, Zuo Y, Gu H, et al. Synchronized delta oscillations correlate with the resting-state functional MRI signal. Proc Natl Acad Sci USA 2007;104(46):18265-9 (Pubitemid 350210855)
112. Gozzi A, Schwarz A, Reese T, et al. Region-specific effects of nicotine on brain activity: a pharmacological MRI study in the drug-naive rat. Neuropsychopharmacology 2006;31(8):1690-703 An example of functional imaging applications applied to preclinical research.
113. Schwarz AJ, Gozzi A, Reese T, et al. Pharmacological modulation of functional connectivity: the correlation structure underlying the phMRI response to d-amphetamine modified by selective dopamine D3 receptor antagonist SB277011A. Magn Reson Imaging 2007;25(6):811-20 (Pubitemid 47081359)
114. Matthews PM, Honey GD, Bullmore ET. Applications of fMRI in translational medicine and clinical practice. Nat Rev Neurosci 2006;7(9):732-44 Although published a few years ago, a paper that still puts the issue of translational use of imaging into persepctive.
115. Tan DS, Thomas GV, Garrett MD, et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 2009;15(5):406-20
116. Murphy P, Koh DM. Imaging in clinical trials. Cancer Imaging 2010;10:Spec no A: S74-82
117. Wong DF, Tauscher J, Grunder G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 2009;34(1):187-203
118. Wise RG, Preston C. What is the value of human FMRI in CNS drug development? Drug Discov Today 2010;15(21-22):973-80
119. Lockhart BP, Walther B. [Biomarkers: «Found in translation»]. Med Sci (Paris) 2009;25(4):423-30
120. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003;2(7):566-80 (Pubitemid 37361748)
121. Thakor NV. Bench to beside: motivation for university industry partnership. Conf Proc IEEE Eng Med Biol Soc 2009;2009:154-6
122. Boccanfuso AM. Why university-industry partnerships matter. Sci Transl Med 2010;2(51):51cm25
123. Evans G, Austin F. Collaborations among academia, government, and industry in the diagnostics space: barriers and some ideas for solutions. Sci Transl Med 2010;2(63):63mr3
124. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60(8):1119-22
125. Dwyer HA, Matthews PB, Azadani A, et al. Computational fluid dynamics simulation of transcatheter aortic valve degeneration. Interact Cardiovasc Thorac Surg 2009;9(2):301-8
126. National Institute of Neurological Disorders and Stroke. National Institutes of Health, 2010. Available from: http://www.ninds.nih.gov/
127. Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 2009;72(5):432-8
128. Longstreth WT Jr, Koepsell TD, Ton TG, et al. The epidemiology of narcolepsy. Sleep 2007;30(1):13-26 (Pubitemid 46098865)
129. Ohayon MM, Priest RG, Zulley J, et al. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 2002;58(12):1826-33 (Pubitemid 34663586)
130. Kessler RC, Demler O, Frank RG, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 2005;352(24):2515-23 Brain disease continues to rise and yet many pharmaceuticals are removing themselves from this space because of costs and lack of objective readouts that can decrease the risk of drug development.
131. National Institute of Mental Health. National Institutes of Health, 2010. Available from: http://www.nimh.nih.gov/index.shtml
132. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50(2):85-94
133. Toth C, Lander J, Wiebe S. The prevalence and impact of chronic pain with neuropathic pain symptoms in the general population. Pain Med 2009;10(5):918-29
134. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38(1):19-28
135. Freburger JK, Holmes GM, Agans RP, et al. The rising prevalence of chronic low back pain. Arch Intern Med 2009;169(3):251-8
136. Reginster JY. The prevalence and burden of arthritis. Rheumatology (Oxford) 2002;41(Suppl 1):3-6
137. Bigal ME, Lipton RB. The epidemiology, burden, and comorbidities of migraine. Neurol Clin 2009;27(2):321-34
138. Tepper SJ. A pivotal moment in 50 years of headache history: the first American Migraine Study. Headache 2008;48(5):730-1; discussion 2
139. Yeargin-Allsopp M, Rice C, Karapurkar T, et al. Prevalence of autism in a US metropolitan area. JAMA 2003;289(1):49-55 (Pubitemid 36026277)
140. Roe CM, Fagan AM, Williams MM, et al. Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology 2011;76(6):501-10
141. Germain DP. Fabry disease. Orphanet J Rare Dis 2010;5:30
142. Van Den Maagdenberg AM, Terwindt GM, Haan J, et al. Genetics of headaches. Handb Clin Neurol 2010;97:85-97
143. Steiger A, Kimura M. Wake and sleep EEG provide biomarkers in depression. J Psychiatr Res 2010;44(4):242-52
144. Polich J, Corey-Bloom J. Alzheimer's disease and P300: review and evaluation of task and modality. Curr Alzheimer Res 2005;2(5):515-25 (Pubitemid 41703671)
145. Wang J, Maurer L. Positron emission tomography: applications in drug discovery and drug development. Curr Top Med Chem 2005;5(11):1053-75 (Pubitemid 41582120)
146. Cherry SR. The 2006 Henry N. Wagner lecture: of mice and men (and positrons) - advances in PET imaging technology. J Nucl Med 2006;47(11):1735-45
147. Wehrl HF, Judenhofer MS, Wiehr S, Pichler BJ. Pre-clinical PET/MR: technological advances and new perspectives in biomedical research. Eur J Nucl Med Mol Imaging 2009;36(Suppl 1):S56-68
148. Strome EM, Doudet DJ. Animal models of neurodegenerative disease: insights from in vivo imaging studies. Mol Imaging Biol 2007;9(4):186-95 (Pubitemid 47028734)
149. Haller S, Pereira VM, Lazeyras F, et al. Magnetic resonance imaging techniques in white matter disease: potentials and limitations. Top Magn Reson Imaging 2009;20(6):301-12
150. Schaeffter T, Dahnke H. Magnetic resonance imaging and spectroscopy. Handb Exp Pharmacol 2008;185(Pt 1):75-90
151. Sauer J, ffytche DH, Ballard C, et al. Differences between Alzheimer's disease and dementia with Lewy bodies: an fMRI study of task-related brain activity. Brain 2006;129(Pt 7):1780-8
152. Henneman WJ, Sluimer JD, Barnes J, et al. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 2009;72(11):999-1007
153. Morra JH, Tu Z, Apostolova LG, et al. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage 2009;45(1 Suppl):S3-15
154. Jack CR Jr, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004;62(4):591-600 An important early paper on the issue of measures of chronic brain disease that will have potential impact on drugs that are disease modifying.
155. Devanand DP, Pradhaban G, Liu X, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 2007;68(11):828-36 (Pubitemid 46568534)
156. Salat DH, Tuch DS, van der Kouwe AJ, et al. White matter pathology isolates the hippocampal formation in Alzheimer's disease. Neurobiol Aging 2010;31(2):244-56
157. Griffith HR, den Hollander JA, Okonkwo OC, et al. Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia. Alzheimers Dement 2008;4(6):421-7
158. Godbolt AK, Waldman AD, MacManus DG, et al. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 2006;66(5):718-22 (Pubitemid 43739827)
159. Frisoni GB, Lorenzi M, Caroli A, et al. In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology 2009;72(17):1504-11
160. Langbaum JB, Chen K, Lee W, et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage 2009;45(4):1107-16
161. Borsook D, Becerra L. Phenotyping central nervous system circuitry in chronic pain using functional MRI: considerations and potential implications in the clinic. Curr Pain Headache Rep 2007;11(3):201-7 (Pubitemid 46851250)